Tempest Tx (TPST): Forecast Levels Chart

Symbol and logo of brand Tempest Therapeutics Inc (TPST)

Tempest Therapeutics bases its research centers in California, utilizing external CDMO contractors for molecule synthesis to minimize operational disruptions. The company's price evolution on the GURU.Markets platform is currently at 7.00. The business relies on the development of metabolic drugs targeting liver and intestinal tumors, which allows for the effective distribution of investment risks across various market segments.

Tempest Therapeutics Corp (TPST): Consensus Target from 07/04/2022 to 11/11/2026
Original product of Tempest Tx

Professional selection of resilient assets is based on comparing actual price action with the average target prices set by leading investment houses. By analyzing the market consensus target for the stock, an investor assesses how quickly experts adapt to fundamental changes, which is critical for Tempest Therapeutics (TPST) due to the high cost of FDA certification and the protection of unique patents for anti-tumor molecules that eliminate pressure from generics.

Competing companies

Analyst Forecast Prices ONC|Price Target Chart Halozyme HALO|RVMD (Revolution Medicines Inc) - Forecast Levels Chart|AAPG - Price Target Chart|Analyst Median Target CG Oncology Therapeutics CGON|URGN (UroGen Pharma Ltd.) - Consensus Target|BCAX: Analyst Forecast Prices|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|CSBR - Consensus Target|XBIT: Consensus Target|CVM - Analyst Consensus Forecast|OS Therapies (OSTX) - Price Target Chart|Radiopharm Theranostics Ltd - Fair Value Consensus|ARTV (Artiva Biotherapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Adlai Nortye Limited ANL|Consensus Target VERU (Veru Inc.)|Analyst Forecast Prices XLO|Analyst Consensus Forecast RENB (Renovaro)|Mural Oncology PLC (MURA) - Average Forecast Price|KAPA - Price Target Chart|OnKure Therapeutics Inc (OKUR) - Consensus Target|w2.cytomed.sg (GDTC) - Price Target Chart|Forecast Levels Chart CRIS (Curis)|APLM (Apollomics Inc.) - Analyst Consensus Forecast|Average Forecast Price Tharimmune Inc THAR|Price Target Chart Advanced Biomed Inc (ADVB)|Analyst Median Target Genprex Inc|Calidi Biotherapeutics, Inc. - Consensus Target|Analyst Forecast Prices SBFM (Sunshine Biopharma Inc.)|XBIO: Consensus Target|Fair Value Consensus SLRX (Salarius Pharmaceuticals Inc)|PPBT (Purple Biotech Corp) - Consensus Target|AONC: Analyst Forecast Prices|BGNE (BeiGene, Ltd.) - Analyst Consensus Forecast|CKPT: Fair Value Consensus|Analyst Consensus Forecast ELEV|ICAD - Average Forecast Price|Price Target Chart Ikena Oncology IKNA|Fair Value Consensus NTBL|Viracta - Analyst Consensus Forecast|MOR - Analyst Consensus Forecast|NAYA Biosciences Inc. (NAYA) - Price Target Chart|Forecast Levels Chart AAPGV (Ascentage Pharma Group International)